Get used to markets with no nuance, says Blackstone’s Kiran Reddy

2023 will be a year to digest what happened in 2022, according to Blackstone’s Kiran Reddy, who said companies need to adjust to discriminating markets that don’t see nuance.

On The BioCentury Show, Reddy, senior managing director in the Blackstone Life Sciences group, discussed his perspective on the year ahead for biopharmas, the impact he anticipates of the Inflation Reduction Act, and the therapeutic areas where there could be step changes...